68 related articles for article (PubMed ID: 11638)
1. Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
Björkman S; Castensson S; Lindeke B; Sievertsson H
Acta Pharm Suec; 1976; 13(4):289-98. PubMed ID: 11638
[No Abstract] [Full Text] [Related]
2. MIF (Pro-Leu-Gly-NH2): failure to affect oxotremorine effects in mice and rats as well as fluphenazine catalepsy or amphetamine hyperactivity in rats.
Björkman S; Lewander T; Zetterström T
J Pharm Pharmacol; 1980 Apr; 32(4):296-7. PubMed ID: 6103063
[No Abstract] [Full Text] [Related]
3. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
Björkman S; Castensson S; Sievertsson H
J Med Chem; 1979 Aug; 22(8):931-5. PubMed ID: 40028
[TBL] [Abstract][Full Text] [Related]
4. On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.
Björkman S; Sievertsson H
Naunyn Schmiedebergs Arch Pharmacol; 1977 Jun; 298(2):79-81. PubMed ID: 18686
[TBL] [Abstract][Full Text] [Related]
5. Nuclear-magnetic-resonance study of aggregations and conformations of melanostatin and related peptides.
Higashijima T; Tasumi M; Miyazawa T; Miyoshi M
Eur J Biochem; 1978 Sep; 89(2):543-56. PubMed ID: 30631
[TBL] [Abstract][Full Text] [Related]
6. New evidence that demonstrates that L-pro-L-leu-L-gly-NH2 might be the natural MIF.
Vivas A; Celis ME
Acta Physiol Lat Am; 1977; 27(4):177-82. PubMed ID: 31762
[TBL] [Abstract][Full Text] [Related]
7. L-dopa potentiating analogs of Pro-Leu-Gly-NH2 with oral efficacy.
Albrecht HP; Hofman HP; Klebe G; Kreiskott H
Boll Chim Farm; 1991 Feb; 130(2):55-9. PubMed ID: 1678611
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effects of Pro-Leu-Gly NH2 and L-leucine on tremorine-induced tremor and rigidity in rats.
Dickinson SL; Slater P
J Pharm Pharmacol; 1982 May; 34(5):336-7. PubMed ID: 6123577
[No Abstract] [Full Text] [Related]
9. Conformational preference of Leu side chain in melanostatin in DMSO.
Sasidhar YU; Dhingra MM; Saran A
Indian J Biochem Biophys; 1990 Apr; 27(2):69-75. PubMed ID: 1972373
[TBL] [Abstract][Full Text] [Related]
10. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat.
Bhargava HN; Kim HS
J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229
[TBL] [Abstract][Full Text] [Related]
11. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.
Castensson S; Sievertsson H; Lindeke B; Sum CY
FEBS Lett; 1974 Aug; 44(1):101-5. PubMed ID: 4212370
[No Abstract] [Full Text] [Related]
12. Effects of Pro-Leu-Gly-NH2 (MIF) on the antinociceptive and thermoregulatory actions of morphine and oxotremorine.
Slater P; Dickinson SL
J Pharm Pharmacol; 1982 Feb; 34(2):113-5. PubMed ID: 6121869
[No Abstract] [Full Text] [Related]
13. Structural specificity of MIF-1 and Tyr-MIF-1 in augmenting GABA-stimulated benzodiazepine receptor binding.
Miller LG; Kastin AJ; Roy RB; Gaver A; Fischman AJ; Horvath A
Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):365-8. PubMed ID: 2908009
[TBL] [Abstract][Full Text] [Related]
14. Effects of AIT-082, a purine derivative, on tremor induced by arecoline or oxotremorine in mice.
Nannan G; Runmei Y; Fusheng L; Shoulan Z; Guangqing L
Pharmacology; 2007; 80(1):21-6. PubMed ID: 17496436
[TBL] [Abstract][Full Text] [Related]
15. Effect of beta-adrenergic blocking agents, with differing ancillary properties on oxotremorine induced tremor in mice.
Alkondon M; Ray A; Sen P
Indian J Exp Biol; 1984 Jul; 22(7):382-3. PubMed ID: 6150896
[No Abstract] [Full Text] [Related]
16. Naloxone-like protective effect of MIF-1 (Pro-Leu-Gly-NH2) on hemorrhagic shock.
Krause W; Nieber K; Ehrlich A; Bienert M; Oehme P
Pharmazie; 1984 May; 39(5):352-3. PubMed ID: 6147863
[No Abstract] [Full Text] [Related]
17. [Use of the peptide hormone melanostatin and its analogs for the synthesis of new antitumor compounds].
Lagova ND; Smirnova ZS; Sof'ina ZP; Smirnova LI; Kashnikova NM
Vopr Onkol; 1988; 34(1):73-9. PubMed ID: 2893489
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone.
Osbahr AJ; Nemeroff CB; Luttinger D; Mason GA; Prange AJ
J Pharmacol Exp Ther; 1981 Jun; 217(3):645-51. PubMed ID: 6112261
[TBL] [Abstract][Full Text] [Related]
19. Neurotropic and pituitary effects of melanostatin (MIF), thyroliberin (TRH) and structurally related peptides.
Björkman S
Acta Pharm Suec; 1980; 17(6):352. PubMed ID: 6111892
[No Abstract] [Full Text] [Related]
20. [Effect of melanostatin on the central nervous system].
Chepurnova NE; Borzenkov VM; Chepurnov SA
Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (2):36-42. PubMed ID: 6132624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
